ATE549347T1 - Gene von säugetiere, und damit verbundene reagentien, methoden - Google Patents

Gene von säugetiere, und damit verbundene reagentien, methoden

Info

Publication number
ATE549347T1
ATE549347T1 AT10179792T AT10179792T ATE549347T1 AT E549347 T1 ATE549347 T1 AT E549347T1 AT 10179792 T AT10179792 T AT 10179792T AT 10179792 T AT10179792 T AT 10179792T AT E549347 T1 ATE549347 T1 AT E549347T1
Authority
AT
Austria
Prior art keywords
genes
methods
mammal
associated reagents
reagents
Prior art date
Application number
AT10179792T
Other languages
English (en)
Inventor
Daniel M Gorman
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE549347T1 publication Critical patent/ATE549347T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
AT10179792T 2000-09-08 2001-09-07 Gene von säugetiere, und damit verbundene reagentien, methoden ATE549347T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23126700P 2000-09-08 2000-09-08

Publications (1)

Publication Number Publication Date
ATE549347T1 true ATE549347T1 (de) 2012-03-15

Family

ID=22868480

Family Applications (1)

Application Number Title Priority Date Filing Date
AT10179792T ATE549347T1 (de) 2000-09-08 2001-09-07 Gene von säugetiere, und damit verbundene reagentien, methoden

Country Status (9)

Country Link
US (6) US7060800B2 (de)
EP (2) EP2298789B1 (de)
JP (2) JP2004509617A (de)
CN (1) CN1452633A (de)
AT (1) ATE549347T1 (de)
AU (1) AU2001294541A1 (de)
CA (1) CA2419979A1 (de)
MX (1) MXPA03002049A (de)
WO (1) WO2002020569A2 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034769A2 (en) * 1999-11-05 2001-05-17 Human Genome Sciences, Inc. 24 human secreted proteins
ATE458814T1 (de) 1999-12-03 2010-03-15 Zymogenetics Inc Menschliches zytokinrezeptor
US20030170823A1 (en) 1999-12-23 2003-09-11 Presnell Scott R. Novel cytokine ZCYTO18
EP1337636B1 (de) 2000-08-08 2006-10-18 ZymoGenetics, Inc. Lösliche zcyctor 11 cytokinrezeptoren
US7358353B2 (en) 2000-08-22 2008-04-15 Agensys, Inc. Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
CA2420543C (en) * 2000-08-22 2013-04-02 Agensys, Inc. Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
EP2298789B1 (de) * 2000-09-08 2012-03-14 Schering Corporation Gene von Säugetiere, und damit verbundene Reagentien, Methoden
JP2004514448A (ja) * 2000-11-28 2004-05-20 アムジェン　インコーポレイテッド トランスフォーミング増殖因子β関連分子およびその使用
PT1356046E (pt) * 2000-11-28 2010-03-09 Zymogenetics L L C Receptor de citocina zcytor19
JP2005503765A (ja) 2001-03-27 2005-02-10 ザイモジェネティクス，インコーポレイティド ヒトサイトカイン受容体
US7910313B2 (en) 2001-04-20 2011-03-22 Zymogenetics, Inc. Cytokine protein family
US7038032B2 (en) 2001-04-20 2006-05-02 Zymogenetics, Inc. Cytokine protein family
JPWO2003031620A1 (ja) * 2001-10-02 2005-01-27 持田製薬株式会社 新規クラスｉｉサイトカイン受容体
US7033787B2 (en) * 2001-12-21 2006-04-25 Ludwig Institute For Cancer Research Isolated cytokine receptor LICR-2
EP1546358A4 (de) 2002-03-22 2006-06-07 Zymogenetics Inc Anti-il-tif-antikörper und verfahren zur verwendung bei entzündung
RU2004133765A (ru) 2002-04-19 2005-06-27 ЗАЙМОДЖЕНЕТИКС Инк. (US) Рецептор цитокина
US7141381B2 (en) 2002-04-25 2006-11-28 Bristol-Myers Squibb Company Human leucine-rich repeat-containing proteins specifically expressed in the nervous system
DK2298278T3 (en) 2002-06-07 2016-02-01 Dyax Corp Prevention and reduction of blood loss and inflammatory response
US7135170B2 (en) 2002-10-23 2006-11-14 Zymogenetics, Inc. Methods for treating viral infection using IL-28 and IL-29
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
WO2004072263A2 (en) * 2003-02-10 2004-08-26 Agensys, Inc. Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
EA009124B1 (ru) 2003-03-24 2007-10-26 Займоджинетикс, Инк. Антитела против il-20 и связывающие партнеры, а также способы их применения при воспалении
EP2251352A1 (de) 2003-08-07 2010-11-17 ZymoGenetics, L.L.C. Homogene Präparate von IL-28 und IL-29
DK1663281T3 (en) * 2003-08-29 2014-03-17 Dyax Corp POLY-PEGYLED PROTEASE INHIBITORS
GB0325038D0 (en) 2003-10-27 2003-12-03 Ares Trading Sa Protein
JP4896005B2 (ja) 2004-04-02 2012-03-14 ザイモジェネティクス リミテッド ライアビリティ カンパニー Ｉｌ−２８およびｉｌ−２９システイン変異体を用いるウイルス感染を治療するための方法
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP2389944A1 (de) 2004-07-29 2011-11-30 ZymoGenetics, L.L.C. Nutzung von IL-28 und IL-29 zur Behandlung von Krebs
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
CA2584157C (en) 2004-10-22 2014-10-14 Zymogenetics, Inc. Anti-il-22ra antibodies and binding partners and methods of using in inflammation
WO2006114387A2 (en) * 2005-04-26 2006-11-02 Laboratoires Serono S.A. Insp163 polypeptides for the treatment or prevention of cancer and arthritis
GB0423973D0 (en) * 2004-10-28 2004-12-01 Ares Trading Sa C1q related points
EP1909821A2 (de) 2005-07-20 2008-04-16 ZymoGenetics, Inc. Verwendung von verkürzten cystein il28 und il29mutanten zur behandlung von krebs und autoimmunkrankheiten
EP1790664A1 (de) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoklonale Antikörper gegen Claudin-18 zur Behandlung von Krebs
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
BRPI0810893A2 (pt) * 2007-04-11 2014-10-29 Alcon Res Ltd Uso de inibidor de tnf-alfa a um anti-histamínico para tratar rinite alérgica e conjuntivite, e composição farmacêutica compreendendo os referidos compostos.
CN103446579B (zh) 2007-09-28 2015-04-22 普托拉制药有限公司 用于因子xa抑制剂的解毒剂和其使用方法
EP2414517B1 (de) 2009-03-30 2016-09-21 Portola Pharmaceuticals, Inc. Gegenmittel für faktor-xa-hemmer und verwendungsverfahren dafür
US9056106B2 (en) 2009-07-15 2015-06-16 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor Xa inhibitors and methods of using the same
AU2010300421B2 (en) * 2009-10-01 2014-01-23 Alcon Research, Ltd. Olopatadine compositions and uses thereof
US8609355B2 (en) 2011-07-26 2013-12-17 Indicator Systems International, Inc. Assays for the detection of microbes
EP3626254A1 (de) 2012-03-16 2020-03-25 University Health Network Lösliches toso protein und dessen verwendung zur behandlung von autoimmunerkrankungen
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
SG11201501286PA (en) 2012-08-23 2015-05-28 Agensys Inc Antibody drug conjugates (adc) that bind to 158p1d7 proteins
KR102381936B1 (ko) 2012-11-13 2022-04-01 비온테크 에스이 클라우딘 발현 암 질환의 치료제
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
JP6538707B2 (ja) 2014-03-07 2019-07-03 ユニバーシティ ヘルス ネットワーク 免疫応答を調節するための方法及び組成物
KR102555955B1 (ko) 2014-03-27 2023-07-18 다케다 파머수티컬 컴패니 리미티드 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
WO2017011275A1 (en) 2015-07-10 2017-01-19 Nersissian Aram M Factor viii protein compositions and methods of treating hemophilia a
CA2993009A1 (en) 2015-07-31 2017-02-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
WO2017066719A2 (en) 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Hu specific interfering agents
AU2018206560A1 (en) 2017-01-04 2019-07-18 Research Institute At Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
US11564982B2 (en) 2017-01-04 2023-01-31 Research Institute At Nationwide Children's Hospital DNABII vaccines and antibodies with enhanced activity
CA3056088A1 (en) 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
CN110229226B (zh) * 2019-05-23 2023-04-11 西安医学院 一种slfn11截断肽及其应用和药物组合物
CA3145385A1 (en) 2019-07-08 2021-01-14 Steven D. Goodman Antibody compositions for disrupting biofilms

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US88426A (en) 1869-03-30 Improved velocipede
US2736896A (en) 1951-12-04 1956-02-28 Sperry Rand Corp Horn antenna system
GB1319315A (en) 1969-06-19 1973-06-06 Citizen Watch Co Ltd Calendar timepiece
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4859609A (en) 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
EP2298789B1 (de) * 2000-09-08 2012-03-14 Schering Corporation Gene von Säugetiere, und damit verbundene Reagentien, Methoden
US11068393B2 (en) 2019-10-17 2021-07-20 Microsoft Technology Licensing, Llc Enhanced concurrency garbage collection stack scanning

Also Published As

Publication number Publication date
US7060800B2 (en) 2006-06-13
US7893211B2 (en) 2011-02-22
JP2009039124A (ja) 2009-02-26
US7427668B2 (en) 2008-09-23
WO2002020569A3 (en) 2003-01-23
EP1315743B1 (de) 2012-11-07
CN1452633A (zh) 2003-10-29
EP1315743A2 (de) 2003-06-04
US20020142292A1 (en) 2002-10-03
EP2298789B1 (de) 2012-03-14
US20110165165A1 (en) 2011-07-07
JP2004509617A (ja) 2004-04-02
US20100104576A1 (en) 2010-04-29
MXPA03002049A (es) 2003-07-24
WO2002020569A2 (en) 2002-03-14
CA2419979A1 (en) 2002-03-14
US8426573B2 (en) 2013-04-23
US20090155242A1 (en) 2009-06-18
EP2298789A1 (de) 2011-03-23
US7696317B2 (en) 2010-04-13
US20120164147A1 (en) 2012-06-28
US8148507B2 (en) 2012-04-03
US20050186620A1 (en) 2005-08-25
AU2001294541A1 (en) 2002-03-22

Similar Documents

Publication Publication Date Title
ATE549347T1 (de) Gene von säugetiere, und damit verbundene reagentien, methoden
NO20025354L (no) Pattedyr-reseptorproteiner; beslektede reagenser og fremgangsmåter
NO20062886L (no) IL-23 og dens reseptor, beslektede reagenser og fremgangsmater
CY1109093T1 (el) Πρωτεϊνες των υποδοχεων θηλαστικων, σχετικα αντιδραστηρια και σχετικες μεθοδοι
ATE516304T1 (de) Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden
ATE397660T1 (de) Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
LU91756I2 (fr) Denosumab
EP2305715A3 (de) Monoklonaler Antikörper gegen das Osteoprotegerin-bindenden Protein
WO2001090358A3 (en) Mammalian receptor proteins; related reagents and methods
BR9811039A (pt) Citocina de mamìferos: interleucina-b30 e reagentes relacionados
EP1433792A3 (de) Menschlische-rezeptor Proteine; verwandte Reagenzien und Methoden
WO1999046379A3 (en) Human receptor proteins; related reagents and methods
ATE363070T1 (de) Auswertung von biologischen mitteln in lebenden zielzellen
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
EA200300246A1 (ru) Ген и белок, ассоциированные с шизофренией
ATE265533T1 (de) Saeugetierchemokine
ATE294237T1 (de) S?ugetier thymokingene
WO2005065711A3 (en) Mammalian receptor proteins; related reagents and methods
WO2003022992A3 (en) Mammalian genes; related reagents
CY1114280T1 (el) Αντισωματα ανταγωνιστων των κυτοκινων θηλαστικων ή οι υποδοχεις τους για την αγωγη της αλλεργιας